Novel Prostate Cancer Therapeutic

Inventors at the University of Missouri have demonstrated the proof of concept for combinational therapy of prostate cancer using bacteriotherapy in conjunction with hormone therapy, immunotherapy, or chemotherapy.

Background

Prostate cancer (PC) has a high mortality rate and is one of the most commonly occurring cancers globally. Although chemotherapy and hormone therapy (androgen deprivation therapy, ADT) are commonly used frontline treatments for this disease, they suffer from broad off-target effects and lack of durable efficacy, especially against neuroendocrine prostate cancer (NEPC), a deadly PC subtype. In fact, ADT causes the emergence of therapy resistant NEPC. The median survival benefit for patients treated with chemotherapy and ADT is less than 5 months.

Taking these factors into consideration researchers at the University of Missouri have developed a novel therapy combining an engineered tumor-targeting bacterial strain with a number of chemotherapeutic and immunotherapeutic agents. These novel therapies have been demonstrated successful in animal models, have been shown to target NEPC, and have the potential to revolutionize prostate cancer therapy.

Applications

• Prostate cancer therapy
• Potential for application in additional types of cancer
• Prostate cancer targeted therapeutic load delivery vehicle

Advantages

• Cost effective
• Target NEPC

Applications

• Prostate cancer therapy
• Potential for application in additional types of cancer
• Prostate cancer targeted therapeutic load delivery vehicle

Advantages

• Cost effective
• Target NEPC

State of Development: Efficacy has been demonstrated in mouse models of prostate cancer

Additional Details